MN SF 4189
died on adjournmentCommissioner of health direction to study and report on activities to support innovations in cell and gene therapy to treat rare diseases
Minnesota · 2025-2026 · upper
Quick answers
Did MN SF 4189 pass?
No. MN SF 4189 died when the 2025-2026 session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-04-07): Author added Miller
What is MN SF 4189 about?
MN SF 4189 is a bill in the 2025-2026 titled “Commissioner of health direction to study and report on activities to support innovations in cell and gene therapy to treat rare diseases”.
Who sponsors MN SF 4189?
Coleman is the primary sponsor of MN SF 4189, joined by 4 cosponsors.
- Introduced
- 2026-03-05
- Latest action
- 2026-04-07 — Author added Miller
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Colemanprimary
- Boldoncosponsor
- Rasmussoncosponsor
- Hemmingsen-Jaegercosponsor
- Millercosponsor
Committees
Not provided by source.
Action timeline
2026-03-05
Introduction and first reading
introduction
2026-03-05
Referred to Health and Human Services
referral-committee
2026-03-23
Author added Rasmusson
2026-03-25
Author added Hemmingsen-Jaeger
2026-04-07
Author added Miller
Versions
- Introduction — 2026-03-04Compare
Documents
Votes
Not provided by source.
Related bills
- Companion bill: HF 4064
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:24:48.331508Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=MN&identifier=SF 4189. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.